N-of-One, a Lexington, Mass.-based precision medicine oncology decision support company, received $7m in Series B funding.
Backers included Providence Ventures and Excel Venture Management.
The company intends to use the funds to expand its R&D and and global sales and marketing efforts.
Led by Chris Cournoyer, CEO, N-of-One provides physicians with oncology treatment options through the analysis of each patient’s unique molecular profile, including integrating multiple molecular tests and information from its proprietary database.
Working with hospital systems, cancer centers, and commercial labs, the company’s solutions have identified treatment options, including molecularly matched clinical trials, for tens of thousands of cancer patients.